• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0364 +0.0021 (+6.12%)
Streaming Delayed Price Updated: 2:06 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 939,441
Open 0.0345
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0343
Today's Range 0.0338 - 0.0380
52wk Range 0.0150 - 0.1100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Oncotelic Therapeutics Inc. (OTLC) Expands Beyond Biotech Through AI-Robotics Pivot, Unlocking New Value in GMP Automation
April 16, 2026
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports FY 2025 Net Income of $249 Million
April 16, 2026
Via Investor Brand Network
Topics Artificial Intelligence

Performance

YTD
-53.2%
-53.2%
1 Month
-1.1%
-1.1%
3 Month
-47.9%
-47.9%
6 Month
-59.8%
-59.8%
1 Year
-36.7%
-36.7%

More News

Read More
News headline image
Oncotelic Therapeutics Reports FY 2025 Results Highlighting $249M Net Income and JV Pipeline Progress
April 16, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In AINewsWire Editorial On AI-Driven Pharma Manufacturing
April 10, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Strengthening Position with AI-Driven Tech in Automated Compliance Space
April 10, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
AINewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In Editorial On AI-Driven Transformation of Pharmaceutical Manufacturing
April 09, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
April 09, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
April 09, 2026
From AINewsWire
Via GlobeNewswire
AINewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in AINewsWire Editorial on AI-Driven Pharma Compliance
April 08, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research
April 08, 2026
Via Investor Brand Network
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
April 07, 2026
Via Investor Brand Network
Topics Artificial Intelligence
TechMediaBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Enters Robotics And AI Biopharma Partnership With Oncotelic Therapeutics (OTCQB: OTLC)
April 06, 2026
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Partners with TechForce Robotics to Advance AI-Enabled GMP Automation Platform
April 02, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
AI-Driven Compliance Gamechanger in Pharma Manufacturing and Regulatory Standards
April 07, 2026
From AINewsWire
Via GlobeNewswire
News headline image
Oncotelic Therapeutics Announces Strategic Partnership with TechForce Robotics to Commercialize PDAOAI-Enhanced GMP Robotics Platform
April 02, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026
March 24, 2026
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
March 23, 2026
Via Investor Brand Network
Topics Artificial Intelligence Regulatory Compliance
News headline image
Growth Stocks: NGTF, AMLM, CSDX, OTLC, ECGI Across Robotics, Precious Metals, MedTech and Blockchain
March 04, 2026
Via AB Newswire
Topics Economy Intellectual Property
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends
February 23, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
February 23, 2026
From NetworkNewsWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS and Oncology Momentum
February 20, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution
February 20, 2026
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From BioMedWire
Via GlobeNewswire
BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
February 18, 2026
Via Investor Brand Network
Topics Intellectual Property

Frequently Asked Questions

Is Oncotelic Therapeutcs Inc publicly traded?
Yes, Oncotelic Therapeutcs Inc is publicly traded.
What exchange does Oncotelic Therapeutcs Inc trade on?
Oncotelic Therapeutcs Inc trades on the OTC Traded
What is the ticker symbol for Oncotelic Therapeutcs Inc?
The ticker symbol for Oncotelic Therapeutcs Inc is OTLC on the OTC Traded
What is the current price of Oncotelic Therapeutcs Inc?
The current price of Oncotelic Therapeutcs Inc is 0.0364
When was Oncotelic Therapeutcs Inc last traded?
The last trade of Oncotelic Therapeutcs Inc was at 04/16/26 02:06 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap